SJX-653, a Novel Selective NK3 Antagonist in Clinical Development as a Once-Daily Non-Hormonal Treatment for Menopausal Vasomotor Symptoms, or “Hot Flashes”
Premier Healthcare Investors RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors Participate in Financing
Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the treatment of women’s health and neuroendocrine disorders, announced today the completion of a $44 million Series C financing. Proceeds from the financing will be used to advance SJX-653, a novel, potent, and selective neurokinin-3 (NK3) receptor antagonist in clinical development as a once-daily non-hormonal treatment for menopausal vasomotor symptoms (commonly referred to as “hot flashes”).
Leading healthcare investors participated in the Series C financing, including RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors. To date, Sojournix has raised a total of $70 million in capital, including $7 million in a Series A financing, $19 million in a Series B financing and $44 million in the Series C financing announced today.
“With this financing we are well-positioned with an outstanding syndicate of investors to rapidly progress clinical development of SJX-653 for the treatment of moderate to severe vasomotor symptoms due to menopause and additional potential indications,” said Dan Grau, President, CEO, and co-founder of Sojournix. “By advancing SJX-653, we hope to address the large and well-recognized unmet medical need among patients for a safe and effective non-hormonal treatment option.”
“Our philosophy is to invest in companies that are developing the best agents, from the most promising emerging drug classes, spearheaded by outstanding management teams – and all three of these elements are present with Sojournix,” said Jamie Topper, M.D., Ph.D., Managing General Partner of Frazier Healthcare Partners’ Life Sciences team. “We look forward to working with Dan and the Sojournix team as they develop the full clinical and commercial potential of SJX-653.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.